Gibson C Michael, Ajmi Issameddine, von Koenig Cajetan L, Turco Mark A, Stone Gregg W
Beth Israel Lahey, USA; Baim Institute for Clinical Research (FKA Harvard Clinical Research Institute), USA; Harvard Medical School, USA.
Helios Frankenwaldklinik Kronach, Freisener Strasse 41, 96317 Kronach, Germany.
Cardiovasc Revasc Med. 2022 Dec;45:9-14. doi: 10.1016/j.carrev.2022.07.007. Epub 2022 Jul 28.
Despite successful primary percutaneous coronary intervention (PCI) for treatment of ST-segment elevation myocardial infarction (STEMI), myocardial salvage is frequently suboptimal resulting in large infarctions with increased rates of heart failure and death. Microvascular dysfunction after the procedure is frequently present and contributes directly to poor outcomes in STEMI. Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) is a novel technology designed to mitigate microvascular dysfunction in STEMI. Non-randomized studies have suggested that PiCSO use during primary PCI in STEMI is safe, improves microvascular perfusion and reduces infarct size. Randomized trials are ongoing to investigate the safety and effectiveness of PiCSO in high-risk patients with anterior STEMI undergoing primary PCI.
尽管经皮冠状动脉介入治疗(PCI)在治疗ST段抬高型心肌梗死(STEMI)方面取得了成功,但心肌挽救往往不尽人意,导致大面积梗死,心力衰竭和死亡率增加。术后微血管功能障碍经常出现,并直接导致STEMI患者预后不良。压力控制间歇性冠状静脉窦闭塞(PiCSO)是一种旨在减轻STEMI微血管功能障碍的新技术。非随机研究表明,在STEMI的直接PCI过程中使用PiCSO是安全的,可改善微血管灌注并缩小梗死面积。目前正在进行随机试验,以研究PiCSO在接受直接PCI的高危前壁STEMI患者中的安全性和有效性。